Production (Stage)
Pacific Biosciences of California, Inc.
PACB
$1.14
$0.1414.00%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -23.99% | -23.19% | 2.14% | 29.24% | 49.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -23.99% | -23.19% | 2.14% | 29.24% | 49.54% |
| Cost of Revenue | -21.13% | -25.42% | 2.18% | 33.10% | 64.98% |
| Gross Profit | -30.54% | -17.74% | 2.06% | 21.55% | 23.13% |
| SG&A Expenses | -1.34% | 3.06% | -2.28% | 5.78% | 8.01% |
| Depreciation & Amortization | 2,513.38% | 236.60% | 1,253.66% | 1,853.87% | 1,247.22% |
| Other Operating Expenses | 47.44% | -70.95% | -- | -- | -- |
| Total Operating Expenses | 54.71% | -13.00% | -2.47% | 10.93% | 17.83% |
| Operating Income | -105.14% | 6.41% | 5.05% | -1.98% | -3.74% |
| Income Before Tax | -113.33% | 2.71% | -23.50% | -29.01% | 3.88% |
| Income Tax Expenses | 100.12% | 102.77% | 93.29% | -- | -- |
| Earnings from Continuing Operations | -121.54% | -1.02% | -27.54% | -25.43% | 7.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -121.54% | -1.02% | -27.54% | -25.43% | 7.44% |
| EBIT | -105.14% | 6.41% | 5.05% | -1.98% | -3.74% |
| EBITDA | 16.41% | 14.23% | 15.15% | 5.83% | 1.61% |
| EPS Basic | -100.76% | 5.92% | -13.89% | -10.13% | 18.48% |
| Normalized Basic EPS | -89.88% | 10.97% | 14.15% | 11.64% | 14.21% |
| EPS Diluted | -100.92% | 5.87% | -14.33% | -10.55% | 18.35% |
| Normalized Diluted EPS | -87.75% | 13.08% | 14.15% | 11.64% | 14.21% |
| Average Basic Shares Outstanding | 8.00% | 8.25% | 11.16% | 12.78% | 13.50% |
| Average Diluted Shares Outstanding | 10.30% | 10.60% | 11.16% | 12.78% | 13.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |